Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1998-07-14
2000-12-26
Fredman, Jeffrey
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
4352542, 435 691, 536 231, 536 243, 536 2431, 536 2432, 536 2433, C12Q 168, C12N 119, C12P 2100, C07H 2102, C07H 2104
Patent
active
061657190
ABSTRACT:
The present invention is based on the discovery and cloning of the human small conductance calcium activated potassium channel type 3 (hKCa3/KCNN3) gene, which is expressed in neuronal cells, skeletal muscle, heart, and lymphocytes. Alterations in the hKCa3/KCNN3 gene or its protein product may enhance susceptibility to schizophrenia and/or bipolar disorder. hKCa3/KCNN3 may be involved in neuropsychiatric, neurological, neuromuscular, and immunological disorders. Substantially purified hKCa3/KNN3 polypeptides and polynucleotides are provided. Antibodies which bind to hKCa3/KCNN3 polypeptides are also disclosed. A method for identifying a compound which affects hKCa3/KCNN3 polynucleotide or polypeptide is provided. A method for diagnosis and determining the prognosis and treatment regimen of a subject having or at risk of having a hKCa3/KCNN3-associated disorder is also provided. A method of treating a subject having or at risk of having an hKCa3/KCNN3-associated disorder by administering a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2 is also provided. A formulation for administration of hKCa3/KCNN3 to a patient of a therapeutically effective amount of hKCa3/KCNN3 polypeptide is provided. Kits useful for detecting the presence of hKCa3/KCNN3 polypeptide or polynucleotide in a sample from a subject having a hKCa3/KCNN3-associated disorder are provided. Transgenic nonhuman animals having a transgene encoding hKCa3/KCNN3 are also described.
REFERENCES:
Imbert et al., "Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats", Nature Genetics, vol. 14, pp. 285-291, Nov. 1996.
Stratagene catalog, p. 39, 1988.
Takahiro M. Ishii, A human intermediate conductance calcium-activated potassium channel, Oct. 1997, Neurobiology, vol. 94 pp. 11651-11656.
Gillian P. Bates, Tansgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions, Nov. 1997, Molecular Medicine Today.
P Sanjeeva Reddy, The complex pathology of trinucleotide repeats, Nucleus and gene expression, pp. 364-372.
Georges Imbert, Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats, Nov. 1996, Nature Genetics vol. 14 No. 3.
M. Kohler, Small-Conductance, Calcium-Activated Potassium Channels from Mammalian Brain, Sep. 1996, Science, vol. 273 pp. 1625-1764.
William J. Joiner, hSK4, a member of a novel subfamily of calcium-activated potassium channels, Sep. 1997, Neurobiology, vol. 94 pp. 11013-11018.
Kohler et al., Small Conductance, Calcium-Activated Potassium Channels from Mammalian Brain. Science. Sep. 20, 1996, vol. 273, pp. 1709-1714, expecially figures 1A and 1C on p. 1710.
Chandy K. George
Fantino Emmanuelle
Gargus J. Jay
Gutman George
Kalman Katarin
Chakrabarti Arun
Fredman Jeffrey
Haile Lisa A.
The Regents of the University of California
LandOfFree
hKCa3/KCNN3 small conductance calcium activated potassium channe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with hKCa3/KCNN3 small conductance calcium activated potassium channe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hKCa3/KCNN3 small conductance calcium activated potassium channe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993172